Urinary symptom flare after brachytherapy for prostate cancer is associated with erectile dysfunction and more urinary symptoms before implantation

BJU International

Volumn 98, Issue 5, 2006, Pages 979-981

  Lehrer, Steven ^a   Cesaretti, Jamie ^a   Stone, Nelson N ^b   Stock, Richard G ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Brachytherapy; Prostate cancer; SHIM; Symptom flare

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; HORMONE; IODINE 125; PROSTATE SPECIFIC ANTIGEN; SILDENAFIL; TERAZOSIN;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; DISEASE EXACERBATION; ERECTILE DYSFUNCTION; HIGH RISK POPULATION; HUMAN; IMPLANTATION; INTERNATIONAL PROSTATE SYMPTOM SCORE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; QUESTIONNAIRE; RADIATION DOSE; RADIOSENSITIVITY; SCORING SYSTEM; SEXUAL FUNCTION; SEXUAL HEALTH INVENTORY FOR MEN; URINARY TRACT DISEASE;

AGED; BRACHYTHERAPY; ERECTILE DYSFUNCTION; HUMANS; IMPOTENCE; MALE; MUTATION; PIPERAZINES; PROSTATIC NEOPLASMS; PROSTATISM; PURINES; QUALITY OF LIFE; RADIATION TOLERANCE; RECURRENCE; RISK FACTORS; SULFONES; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 33749581486     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06398.x     Document Type: Article

References (13)

1. Cesaretti JA, Stone NN, Stock RG. Urinary symptom flare following I-125 prostate brachytherapy. Int J Radiat Oncol Biol Phys 2003; 56: 1085-92
2. Mallick S, Azzouzi R, Cormier L, Peiffert D, Mangin PH. Urinary morbidity after 125I brachytherapy of the prostate. BJU Int 2003; 92: 555-8
3. Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK. Correlation of the American Urological Association symptom index with self-administered versions of the Madsen-Iversen, Boyarsky and Maine Medical Assessment Program symptom indexes. Measurement Committee of the American Urological Association. J Urol 1992; 148: 1558-64
4. Cappelleri JC, Siegel RL, Glasser DB, Osterloh IH, Rosen RC. Relationship between patient self-assessment of erectile dysfunction and the sexual health inventory for men. Clin Ther 2001; 23: 1707-19
5. Kollmeier MA, Stock RG, Stone N. Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality. Int J Radiat Oncol Biol Phys 2003; 57: 645-53
6. Stock RG, Stone NN, Wesson MF, DeWyngaert JK. A modified technique allowing interactive ultrasound-guided three-dimensional transperineal prostate implantation. Int J Radiat Oncol Biol Phys 1995; 32: 219-25
7. Stock RG, Stone NN, Lo YC, Malhado N, Kao J, DeWyngaert JK. Postimplant dosimetry for (125)I prostate implants: definitions and factors affecting outcome. Int J Radiat Oncol Biol Phys 2000; 48: 899-906
8. Anonymous. SPSS Regression Models 13.0. Chicago: SPSS, Inc., 2004, 25-30
9. Braun MH, Sommer F, Haupt G, Mathers MJ, Reifenrath B, Engelmann UH. Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical 'Aging Male' symptoms? Results of the 'Cologne Male Survey'. Eur Urol 2003; 44: 588-94
10. Barqawi A, O'Donnell C, Kumar R, Koul H, Crawford ED. Correlation between LUTS (AUA-SS) and erectile dysfunction (SHIM) in an age-matched racially diverse male population: data from the Prostate Cancer Awareness Week (PCAW). Int J Impot Res 2005; 17: 370-4
11. Rosen R, Altwein J, Boyle P et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44: 637-49
12. Cesaretti JA, Stock RG, Lehrer S et al. ATM sequence variants are predictive of adverse radiotherapy response among patients treated for prostate cancer. Int J Radiat Oncol Biol Phys 2005; 61: 196-202
13. Ohebshalom M, Parker M, Guhring P, Mulhall JP. The efficacy of sildenafil citrate following radiation therapy for prostate cancer: temporal considerations. J Urol 2005; 174: 258-62